| 產品描述： | VU0155041 is a potent, selective positive allosteric modulator (PAM) of mGluR4, with EC50s of 798 nM and 693 nM for human and rat mGluR4, respectively. VU0155041 has potential for the research of Parkinson's disease (PD) |
| 靶點： |
Human mGlu4:798 nM (EC50);Rat mGlu4:693 nM (EC50);GluR |
| 體內研究： |
VU0155041 (31 nmol, 93 nmol; i.c.v.) reverses catalepsy induced by the dopamine D2 receptor antagonist Haloperidol (1.5 mg/kg, i.p.) in rats[1].VU0155041 (93 nnmol, 316 nmol; i.c.v.) reverses Reserpine (HY-N0480)-induced akinesia in rats. Animal Model: Third ventricle cannulated (TVC) Male Sprague-Dawley rats (225-255 g) Dosage: 31 nmol, 93 nmol (10 μL) Administration: Intracerebroventrical injection, after the Haloperidol (1.5 mg/kg) treatment 2 hours Result: Decreased the cataleptic effects of Haloperidol, and the effects still presented 30 min after infusion. |
| 參考文獻： |
1. Niswender CM, et, al. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol. 2008 Nov; 74(5): 1345-58. |
| 溶解性： |
Soluble in DMSO |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
3.163 ml |
15.814 ml |
31.628 ml |
| 5 mM |
0.633 ml |
3.163 ml |
6.326 ml |
| 10 mM |
0.316 ml |
1.581 ml |
3.163 ml |
| 50 mM |
0.063 ml |
0.316 ml |
0.633 ml |
|
| 注意： |
部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京